{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:10:54Z","timestamp":1769908254232,"version":"3.49.0"},"reference-count":47,"publisher":"CSIRO Publishing","issue":"4","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":1612,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>People receiving opioid substitution treatment are a vulnerable population who experience significant health inequities and stigma, but have regular interactions with community pharmacists. Many pharmacists now work collaboratively with other health providers to ensure effective and safe use of medicines, as well as being involved in the prevention and management of chronic health conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIM<\/jats:title>\n                    <jats:p>To explore the role of New Zealand community pharmacists in the provision of opioid substitution treatment and how they perceive their role as part of the wider opioid substitution treatment team.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Semi-structured video interviews with a purposive sample of 13 diverse pharmacists explored their current practices in providing opioid substitution treatment, and their perceived role in the treatment team. Interviews were audio-recorded and transcribed verbatim. Data were coded and analysed using an inductive thematic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>This study found that pharmacists are providing accessible support to a population with known barriers to accessing health care. However, participants also identified challenges with communication and a perceived lack of understanding of the pharmacist role as barriers to collaboration with the wider opioid substitution treatment team.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Collaboration within health-care teams has been shown to improve health outcomes, and pharmacists are well placed to provide health-care services as well as offer valuable insight into clients\u2019 mental and physical wellbeing. Improved communication channels that facilitate information sharing, as well as the opioid substitution treatment team\u2019s recognition of a pharmacist\u2019s role, may facilitate collaboration and, in turn, improve the quality of health care provided to this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/hc20108","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T01:06:07Z","timestamp":1608599167000},"page":"358-367","source":"Crossref","is-referenced-by-count":7,"title":["\u2018We\u2019re just seen as people that give out the methadone\u2026\u2019: exploring the role of community pharmacists in the opioid substitution treatment team"],"prefix":"10.1071","volume":"12","author":[{"given":"Rebecca","family":"Lukey","sequence":"first","affiliation":[{"name":"ADepartment of Primary Health Care and General Practice, University of Otago, Wellington, New Zealand"},{"name":"BCorresponding author. Email: rjlukey@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Gray","sequence":"additional","affiliation":[{"name":"ADepartment of Primary Health Care and General Practice, University of Otago, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Morris","sequence":"additional","affiliation":[{"name":"ADepartment of Primary Health Care and General Practice, University of Otago, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"issue":"7","key":"2025111814140017900_R1","doi-asserted-by":"publisher","DOI":"10.1211\/CP.2018.20205007","article-title":"Risk factors for mortality, hospitalisation and imprisonment in substance misuse patients.","volume":"10","author":"Montgomery Sardar","year":"2018","journal-title":"Clin Pharm."},{"key":"2025111814140017900_R2"},{"key":"2025111814140017900_R3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technol Assess."},{"key":"2025111814140017900_R4","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ."},{"issue":"1","key":"2025111814140017900_R5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.drugpo.2011.05.013","article-title":"An estimation of the prevalence of opioid dependence in New Zealand.","volume":"23","author":"Adamson","year":"2012","journal-title":"Int J Drug Policy."},{"key":"2025111814140017900_R6"},{"key":"2025111814140017900_R7"},{"key":"2025111814140017900_R8"},{"key":"2025111814140017900_R9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12913-018-3120-z","article-title":"Service provision in the wake of a new funding model for community pharmacy.","volume":"18","author":"Harrison","year":"2018","journal-title":"BMC Health Serv Res."},{"key":"2025111814140017900_R10"},{"issue":"6","key":"2025111814140017900_R11","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmv079","article-title":"The evolution of pharmaceutical care for drug misusers.","volume":"32","author":"Robertson","year":"2015","journal-title":"Fam Pract."},{"issue":"2","key":"2025111814140017900_R12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s11096-019-00790-x","article-title":"Community pharmacists\u2019 role in preventing opioid substitution therapy-related deaths: a qualitative investigation into current UK practice.","volume":"41","author":"Yadav","year":"2019","journal-title":"Int J Clin Pharm."},{"issue":"4","key":"2025111814140017900_R13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/pubmed\/fdm064","article-title":"Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland.","volume":"29","author":"Matheson","year":"2007","journal-title":"J Public Health (Oxf)."},{"key":"2025111814140017900_R14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drugpo.2015.11.006","article-title":"Community pharmacy services for people with drug problems over two decades in Scotland: implications for future development.","volume":"27","author":"Matheson","year":"2016","journal-title":"Int J Drug Policy."},{"issue":"1","key":"2025111814140017900_R15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/09595230701710852","article-title":"Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists.","volume":"27","author":"Lawrinson","year":"2008","journal-title":"Drug Alcohol Rev."},{"issue":"6","key":"2025111814140017900_R16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.drugpo.2007.03.002","article-title":"Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.","volume":"19","author":"Winstock","year":"2008","journal-title":"Int J Drug Policy."},{"issue":"1","key":"2025111814140017900_R17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough? An experiment with data saturation and variability.","volume":"18","author":"Guest","year":"2006","journal-title":"Field Methods."},{"issue":"2","key":"2025111814140017900_R18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology.","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol."},{"issue":"1","key":"2025111814140017900_R19","first-page":"28","article-title":"Literature review: pharmacists\u2019 interventions to improve control and management in type 2 diabetes mellitus.","volume":"21","author":"Hassali","year":"2015","journal-title":"Altern Ther Health Med."},{"key":"2025111814140017900_R20"},{"key":"2025111814140017900_R21"},{"issue":"2","key":"2025111814140017900_R22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.sapharm.2017.02.017","article-title":"Collaborative pharmacist prescribing within the opioid substitution treatment program in South Australia: patient and pharmacist views.","volume":"14","author":"Le","year":"2018","journal-title":"Res Social Adm Pharm."},{"key":"2025111814140017900_R23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.healthpol.2015.02.007","article-title":"From \u201cretailers\u201d to health care providers: transforming the role of community pharmacists in chronic disease management.","volume":"119","author":"Mossialos","year":"2015","journal-title":"Health Policy."},{"issue":"6","key":"2025111814140017900_R24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/ijpp.12097","article-title":"A community pharmacist-led anticoagulation management service: attitudes towards a new collaborative model of care in New Zealand.","volume":"22","author":"Shaw","year":"2014","journal-title":"Int J Pharm Pract."},{"issue":"1","key":"2025111814140017900_R25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12875-019-0912-0","article-title":"Community pharmacy integration within the primary care pathway for people with long-term conditions: a focus group study of patients\u2019, pharmacists\u2019 and GPs\u2019 experiences and expectations.","volume":"20","author":"Hindi","year":"2019","journal-title":"BMC Fam Pract."},{"key":"2025111814140017900_R26"},{"key":"2025111814140017900_R27"},{"key":"2025111814140017900_R28"},{"key":"2025111814140017900_R29"},{"key":"2025111814140017900_R30"},{"key":"2025111814140017900_R31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1360-0443.2009.02774.x","article-title":"Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.","volume":"105","author":"Winstock","year":"2010","journal-title":"Addiction."},{"issue":"5","key":"2025111814140017900_R32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1086-5802(16)31315-8","article-title":"Developing collaborative working relationships between pharmacists and physicians.","volume":"41","author":"McDonough","year":"2001","journal-title":"J Am Pharm Assoc."},{"issue":"5","key":"2025111814140017900_R33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1345\/aph.1D419","article-title":"Influential characteristics of physician\/pharmacist collaborative relationships.","volume":"38","author":"Zillich","year":"2004","journal-title":"Ann Pharmacother."},{"key":"2025111814140017900_R34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.sapharm.2005.09.005","article-title":"Factors affecting collaborative care between pharmacists and physicians.","volume":"1","author":"Doucette","year":"2005","journal-title":"Res Social Adm Pharm."},{"key":"2025111814140017900_R35","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1111\/hsc.12705","article-title":"Factors influencing interprofessional collaboration between community pharmacists and general practitioners \u2013 A systematic review.","volume":"27","author":"Bollen","year":"2019","journal-title":"Health Soc Care Community."},{"issue":"3","key":"2025111814140017900_R36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1331\/JAPhA.2011.10068","article-title":"Exploring stages of pharmacist-physician collaboration using the model of collaborative working relationship.","volume":"51","author":"Liu","year":"2011","journal-title":"J Am Pharm Assoc."},{"issue":"4","key":"2025111814140017900_R37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.sapharm.2009.01.002","article-title":"General practitioners\u2019 and pharmacists\u2019 perceptions of the role of community pharmacists in delivering clinical services.","volume":"5","author":"Bryant","year":"2009","journal-title":"Res Social Adm Pharm."},{"issue":"4","key":"2025111814140017900_R38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/ijpp.12080","article-title":"Integrating pharmacists into primary care teams: barriers and facilitators.","volume":"22","author":"Jorgenson","year":"2014","journal-title":"Int J Pharm Pract."},{"key":"2025111814140017900_R39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.sapharm.2010.12.005","article-title":"Integration and differentiation: a conceptual model of general practitioner and community pharmacist collaboration.","volume":"8","author":"Bradley","year":"2012","journal-title":"Res Social Adm Pharm."},{"issue":"1","key":"2025111814140017900_R40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijnurstu.2007.01.015","article-title":"What fosters or prevents interprofessional teamworking in primary and community care? A literature review.","volume":"45","author":"Xyrichis","year":"2008","journal-title":"Int J Nurs Stud."},{"issue":"4","key":"2025111814140017900_R41","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/dar.12032","article-title":"Factors influencing pharmacy services in opioid substitution treatment.","volume":"32","author":"Chaar","year":"2013","journal-title":"Drug Alcohol Rev."},{"issue":"4","key":"2025111814140017900_R42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cptl.2016.03.021","article-title":"Qualitative research methods: why, when, and how to conduct interviews and focus groups in pharmacy research.","volume":"8","author":"Rosenthal","year":"2016","journal-title":"Curr Pharm Teach Learn."},{"issue":"3","key":"2025111814140017900_R43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.7748\/nr2005.01.12.3.32.c5946","article-title":"Telephone interviewing in healthcare research: a summary of the evidence.","volume":"12","author":"Smith","year":"2005","journal-title":"Nurse Res."},{"issue":"6","key":"2025111814140017900_R44","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.addbeh.2011.01.004","article-title":"Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness.","volume":"36","author":"Deering","year":"2011","journal-title":"Addict Behav."},{"issue":"4","key":"2025111814140017900_R45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1447-0349.2011.00795.x","article-title":"Clients\u2019 perceptions of opioid substitution treatment: an input to improving the quality of treatment.","volume":"21","author":"Deering","year":"2012","journal-title":"Int J Ment Health Nurs."},{"key":"2025111814140017900_R46","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s11096-008-9257-9","article-title":"Consumer satisfaction with opioid treatment services at community pharmacies in Australia.","volume":"30","author":"Lea","year":"2008","journal-title":"Pharm World Sci."},{"issue":"8","key":"2025111814140017900_R47","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.sapharm.2019.02.003","article-title":"Perspectives on privacy in the pharmacy: the views of opioid substitution treatment clients.","volume":"15","author":"Le","year":"2019","journal-title":"Res Social Adm Pharm."}],"container-title":["The Journal of Primary Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/12\/4\/358\/223143\/hc20108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/12\/4\/358\/223143\/hc20108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T19:14:09Z","timestamp":1763493249000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/hc\/article\/12\/4\/358\/34992\/We-re-just-seen-as-people-that-give-out-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,22]]},"published-print":{"date-parts":[[2020,12,22]]}},"URL":"https:\/\/doi.org\/10.1071\/hc20108","relation":{},"ISSN":["1172-6156"],"issn-type":[{"value":"1172-6156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]}}}